SPDR S&P Biotech ETF Newsroom

Vertex Pharmaceuticals Analyst Ratings

BenzingaJul 22 11:36 ET

Regeneron Pharmaceuticals Analyst Ratings

BenzingaJul 22 11:34 ET

BioMarin Pharmaceutical Price Target Maintained With a $110.00/Share by Cantor Fitzgerald

Dow JonesJul 22 11:32 ET

Alnylam Pharmaceuticals Price Target Raised to $220.00/Share From $150.00 by Cantor Fitzgerald

Dow JonesJul 22 11:29 ET

Gilead Sciences Analyst Ratings

BenzingaJul 22 11:27 ET

Biomarin Pharmaceutical Analyst Ratings

BenzingaJul 22 11:23 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaJul 22 11:21 ET

Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $70 From $75

MT NewswiresJul 22 09:27 ET

Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925

MT NewswiresJul 22 09:25 ET

Cantor Fitzgerald Adjusts Price Target on Vertex Pharmaceuticals to $480 From $440

MT NewswiresJul 22 09:19 ET

AbbVie Analyst Ratings

BenzingaJul 19 10:42 ET

BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $566 From $500

MT NewswiresJul 19 09:18 ET

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained

MT NewswiresJul 19 09:14 ET

Jefferies Adjusts Price Target on Amgen to $380 From $375

MT NewswiresJul 19 08:41 ET

Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)

TipRanksJul 19 08:17 ET

Vertex Pharmaceuticals Analyst Ratings

BenzingaJul 19 07:04 ET

Exact Sciences (EXAS) Receives a Buy From Piper Sandler

TipRanksJul 19 06:48 ET

Regeneron Pharmaceuticals Analyst Ratings

BenzingaJul 18 11:42 ET

Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,040, Maintains Buy Rating

MT NewswiresJul 18 07:10 ET

Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)

TipRanksJul 18 06:22 ET